A randomised multicentre study of angiography- versus physiologyguided percutaneous coronary intervention in patients with coronary artery disease undergoing TAVI: design and rationale of the FAITAVI trial
EuroIntervention · 2024
DOI: 10.4244/eij-d-23-00679 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2024. Verfasst von Flavio Ribichini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Coronary Artery Disease, Fractional Flow Reserve, Myocardial, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The treatment of coronary artery disease (CAD) in patients with severe aortic valve stenosis (AVS) eligible for transcatheter aortic valve implantation (TAVI) is not supported by clinical evidence, and the role of physiology over anatomy as well as the timing of coronary intervention are not defined. FAITAVI (ClinicalTrials.gov: NCT03360591) is a nationwide prospective, open-label, multicentre, randomised controlled study comparing the angiography-guided versus the physiology-guided coronary revascularisation strategy in patients with combined significant CAD and severe AVS undergoing TAVI. Significant CAD will be defined as coronary stenosis ≥50%, as assessed by visual estimation in vessels ≥2.5 mm. Physiology will be tested by fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR). The study will be conducted at 15 sites in Italy. In the angiography arm, percutaneous coronary intervention (PCI) will be performed either before TAVI, during the TAVI procedure - before or after the valve implantation - or within 1 month±5 days of the valve implantation, left to the operator's decision. In the physiology arm, FFR and iFR will be performed before TAVI, and PCI will be indicated for FFR ≤0.80, otherwise the intervention will be deferred. In case of borderline values (0.81-0.85), FFR and iFR will be repeated after TAVI, with PCI performed when needed. With a sample size of 320 patients, the study is powered to evaluate the primary endpoint (a composite of death, myocardial infarction, stroke, major bleeding, or ischaemia-driven target vessel revascularisation). TAVI indication, strategy and medical treatment will be the same in both groups. After discharge, patients will be contacted at 1, 6, 12 and 24 months after the procedure to assess their general clinical status, and at 12 months for the occurrence of events included in the primary and secondary endpoints. FAITAVI is the first randomised clinical trial to investigate "optimal" percutaneous coronary intervention associated with TAVI in patients with severe AVS and CAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiology, University of Verona, Verona, Italy.
- Department of Cardiac, Thoracic and Vascular Science, University of Padova, Padova, Italy.
- Division of Cardiology, Ospedale dell'Angelo di Mestre, Chirignago-Zelarino, Italy.
- Division of Cardiology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
- Division of Cardiology, ISMETT di Palermo, Palermo, Italy.
- Division of Cardiology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Zitieren
APA
Ribichini, F., Pesarini, G., Fabris, T., Lunardi, M., Barbierato, M., D'Amico, G., Zanchettin, C., Gregori, D., Piva, T., Nicolini, E., Gandolfo, C., Fineschi, M., Petronio, A. S., Berti, S., Caprioglio, F., Saia, F., Sclafani, R., Esposito, G., D'Ascenzo, F., & Tarantini, G. (2024). A randomised multicentre study of angiography- versus physiologyguided percutaneous coronary intervention in patients with coronary artery disease undergoing TAVI: design and rationale of the FAITAVI trial. EuroIntervention. https://doi.org/10.4244/eij-d-23-00679
Vancouver
Ribichini F, Pesarini G, Fabris T, Lunardi M, Barbierato M, D'Amico G, et al. A randomised multicentre study of angiography- versus physiologyguided percutaneous coronary intervention in patients with coronary artery disease undergoing TAVI: design and rationale of the FAITAVI trial. EuroIntervention. 2024. doi:10.4244/eij-d-23-00679
BibTeX
@article{Ribichini2024,
author = {Ribichini, Flavio and Pesarini, Gabriele and Fabris, Tommaso and Lunardi, Mattia and Barbierato, Marco and D'Amico, Gianpiero and Zanchettin, Chiara and Gregori, Dario and Piva, Tommaso and Nicolini, Elisa and Gandolfo, Caterina and Fineschi, Massimo and Petronio, Anna Sonia and Berti, Sergio and Caprioglio, Francesco and Saia, Francesco and Sclafani, Rocco and Esposito, Giovanni and D'Ascenzo, Fabrizio and Tarantini, Giuseppe},
title = {A randomised multicentre study of angiography- versus physiologyguided percutaneous coronary intervention in patients with coronary artery disease undergoing TAVI: design and rationale of the FAITAVI trial},
journal = {EuroIntervention},
year = {2024},
doi = {10.4244/eij-d-23-00679}
}
EUVIMED